ライフサイエンスコーパス: transplant

1 s coronary intervention; or heart/heart-lung transplant).

2 a median of 9.3 years (range: 1.7-40) after transplant.

3 s well as based on their eGFR at the time of transplant.

4 nted to our institution for consideration of transplant.

5 ed if CXCR4 was deleted from donor Tregs pre-transplant.

6 iver transplant and 2 underwent liver-kidney transplant.

7 plications were substantial after allogeneic transplant.

8 ommon during the initial 3 months after lung transplant.

9 ancer diagnosis and haematopoietic stem-cell transplant.

10 recipients of allogeneic hematopoietic cell transplant.

11 ; 67% have survived, including 31 with heart transplant.

12 om 2002 through 2016 with MELD score >=40 at transplant.

13 racteristics and the adjusted probability of transplant.

14 r primary disease is hematopoietic stem cell transplant.

15 d immunosuppression beginning 6 months after transplant.

16 stage renal disease patients awaiting kidney transplant.

17 t autoantigens and alloantigens after kidney transplant.

18 function following IRI and survival of renal transplants.

19 aximizing the number of deceased donor liver transplants.

20 recipients of kidney, liver, lung, and heart transplants.

21 ation in a cohort of 1001 consecutive kidney transplants.

22 t-choice imaging technique to evaluate liver transplants.

23 mitigate them even in patients who cannot be transplanted.

24 se of death, particularly in months 0-3 post-transplant (1.18 per 100 patient-years).

25 , including HIV infection (45%), solid organ transplant (26%), and cirrhosis (22%).

26 ), 5 (83% versus 79%), or 10 years following transplant (61% versus 66%, P = 0.32).

27 Mice were transplanted 7 days postinjection with donor (bm1 or F1)

28 a potential clinical strategy to facilitate transplant acceptance.

29 To understand the impact on transplant activity across the United States, and center

30 Liver transplant activity in 6 centers from these countries wi

31 y was achieved by 22 (71%) organs, that were transplanted after a median preservation time of 18 h, w

32 A total of 132 and 93 liver grafts were transplanted after NRP and HOPE, respectively.

33 d mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients.

34 Stage Liver Disease (MELD) score-based liver transplant allocation was implemented as a fair and obje

35 hether donor-derived MDSCs can protect heart transplant allografts in an antigen-specific manner.

36 y, and categorized as: deceased-donor kidney transplant alone (DD-KA, 68%), living-donor kidney trans

37 lant alone (DD-KA, 68%), living-donor kidney transplant alone (LD-KA, 30%), or SPK (2%).

38 Four patients underwent liver transplant and 2 underwent liver-kidney transplant.

39 s for simultaneous pancreas and kidney (SPK) transplant and define eligibility criteria for those wit

40 Here, we used a syngeneic rat renal transplant and IRI model to evaluate the therapeutic pro

41 We conducted a moss transplant and leaf litter manipulation experiment at th

42 the setting of advanced heart failure, heart transplant and left ventricular assist devices have been

43 health gains between patients who receive a transplant and patients who remain on the waiting list.

44 ational cues for TCAs, we used slice culture transplants and gene expression studies.

45 tumor-initiating cell frequency in secondary transplants and reduced the formation of spontaneous lun

46 A combination of pair-feeding, bone marrow-transplant, and microglial ablation implicate central an

47 ients, younger children, those overweight at transplant, and those with higher cumulative steroid use

48 ly, or in advance of a potential recipient's transplant, and to receive a voucher that can be redeeme

49 ansgenic B6 TEa cells that recognize a major transplant antigen I-Ealpha from Balb/c mice.

50 of a solid organ or hematopoietic stem cell transplant are living longer with a better quality of li

51 s and predicted cardiovascular function post-transplant are used to evaluate the cardiovascular state

52 This Banff Human Organ Transplant (B-HOT) panel is the culmination of previous

53 Transplanted Bbs4(-/-) islets exhibit delayed re-vascula

54 49 T2DM kidney disease patients who received transplant between 2000 and 2016 and survived the first

55 f 616 patients who have received kidney-only transplants between 2000 and 2010 in Western Australia w

56 r necrosis (ATN) and normal kidney (baseline transplant biopsies).

57 ery in this population can help optimize the transplant candidacy of patients with obesity and end-st

58 a history of a pretransplant malignancy for transplant candidacy.

59 outcomes and is incorporated for determining transplant candidate eligibility.

60 obesity on kidney, liver, and cardiothoracic transplant candidates and recipients and explore potenti

61 r 3642 pediatric (age <18 years) kidney-only transplant candidates between December 31, 2012 to Decem

62 knowledge among African American (AA) kidney transplant candidates compared to other races.

63 We examined all nonstatus one adult liver transplant candidates from 2010 to 2014.

64 ardiogenic shock requirements for some heart transplant candidates listed with specific types of trea

65 el reactive antibody [CDC PRA+], C1q+) heart transplant candidates were treated with the combination

66 rogel is an effective strategy for promoting transplanted cell survival under the condition of an iro

67 dian distance between the donor hospital and transplant center increased from 83 to 216 nautical mile

68 Multiple listing (ML) at >1 transplant center is one mechanism to combat the geograp

69 licy changes were undertaken at national and transplant center levels to ensure safe transplantation

70 g patients who traveled >60 miles to reach a transplant center, 41.8% bypassed a closer center and so

71 ased on the establishment of one specialized transplant center, focused on small children, and cooper

72 2020 and April 22, 2020 at a US high-volume transplant center.

73 e hepatology, especially in areas outside of transplant centers.

74 , has become a real matter of concern in the transplant community and may contribute to creating resi

75 rkshop facilitated cooperative engagement of transplant community stakeholders, including pharmaceuti

76 kely to be listed and 105% more likely to be transplanted compared to women with ALD.

77 cipients had a technically successful uterus transplant, compared to 90% in phase 2.

78 beyond-MC HCC from the U.S. Multicenter HCC Transplant Consortium (20 centers, 2002-2013).

79 ) cPR from the United States Multicenter HCC Transplant Consortium (UMHTC), and multivariable predict

80 hysician, nurse (specialist), social worker, transplant coordinator, psychologist, clinical pharmacis

81 n a variety of autoimmune, inflammatory, and transplant disease settings.

82 in VSMCs isolated from 151 multiethnic heart transplant donors.

83 ared trends in the utilization rates (hearts transplanted/donors recovered) of HCV-uninfected (HCV-)

84 outcome in our system and was influenced by transplant dose, inflammatory status of the host, and ty

85 rmation about the processes underlying renal transplant dysfunction and can be used for the developme

86 Educators should prioritize transplant education strategies shown to be associated w

87 ddition of daratumumab (D) to RVd (D-RVd) in transplant-eligible NDMM patients was evaluated.

88 a voucher that can be redeemed for a future transplant facilitated by the NKR.

89 nal Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) score relative to baseline.

90 dialysis mortality are at a higher risk for transplant failure compared with patients with the same

91 dentifies patients at higher risk for kidney transplant failure.

92 exposure is associated with a higher risk of transplant failure.

93 ring the study time period, 168 (15.8%) were transplanted for a diagnosis of ALD.

94 wer than that seen in patients who have been transplanted for chronic liver failure; however long-ter

95 tudies focusing on large cohorts of patients transplanted for primary immunodeficiency are lacking.

96 -term graft survival and outcomes of primary transplants for Fuchs' endothelial dystrophy (FED) were

97 de novo variants were associated with worse transplant-free survival and longer times on the ventila

98 a decision model to estimate probability of transplant-free survival from fetal diagnosis to age 6 y

99 erial hypertension (PAH)-approved drugs, and transplant-free survival of patients with PH-NF1 from th

100 to age 6 years and postnatal restricted mean transplant-free survival time.

101 Adult liver transplants from DO donors increased from 2% in 2002 to

102 n 2002 to 15% in 2017, while pediatric liver transplants from DO donors only increased from <1% to 3%

103 reliable and noninvasive assays to validate transplant function in clinical biomanufacturing.

104 We performed fecal transplant gavage 3 days after middle cerebral artery oc

105 n response to glucose ex vivo and in vivo in transplanted glucose-infused rats.

106 eas there was no catch-up growth in children transplanted >12.

107 Patients with transplants had lower end-diastolic volume index (59.3+/

108 How transplanted haematopoietic stem cells (HSCs) behave soo

109 sociated with a 25% lower risk of post-liver transplant HCC recurrence (95CI 0.57-0.99).

110 A cox-regression analysis for post-liver transplant HCC recurrence highlighted that even after ac

111 bstantial morbidity among hematopoietic cell transplant (HCT) recipients, but the etiology is often n

112 nt, involving several stakeholders such as a transplant hepatologist, transplant surgeon, psychologis

113 of patient travel distances to reach a lung transplant hospital in the United States.

114 from the patient's permanent zip code to the transplant hospital using shared access signature URL ac

115 lier can delay or prevent the need for liver transplant; however, treatment typically occurs later be

116 Therapeutic hematopoietic stem cell transplant (HSCT) during chronic infection generated new

117 of hemodynamic assessment in pediatric heart transplant (HT) patients, expected intracardiac pressure

118 artery vasculopathy (CAV) in pediatric heart transplant (HT) recipients.

119 the understanding of acquired tolerance and transplant immunology represents generations of scientif

120 in patients (n = 181) who received a kidney transplant in Olmsted County, MN (January 1, 1998 to Dec

121 Prior guidelines on timing to transplant in patients with a prior treated malignancy d

122 Many kidneys donated for transplant in the United States are discarded because of

123 minimize the role of geography in access to transplant in the United States, we assessed whether pat

124 atched to very similar kidneys that had been transplanted in France; these discarded kidneys would be

125 asculopathy (CAV) were conducted on patients transplanted in the prevalganciclovir prophylaxis era.

126 have been shown to be a promising tool, even transplanted in vivo, for transducing light stimuli to n

127 r, the outcomes of fetal tissue-derived cell transplants in individuals with Parkinson disease have b

128 These transplants induced mRNAs for >40 to 50 cytokines, chemo

129 currently available regarding the effects of transplant-induced ischemia-reperfusion injury on the ab

130 A total of 737 transplant-ineligible (TIE) patients with newly diagnose

131 that can be transferred via fecal microbial transplant into mice is identified.

132 titudinal gradient in the Alaskan Arctic and transplanted into a common garden.

133 exhibit rapid, aggressive infiltration when transplanted into adult rodent brains.

134 ary human islets and in vivo in human islets transplanted into high-fat diet-fed mice.

135 Mosses native to and transplanted into spruce stands supported generally high

136 lusion: ALC measured at one month post-heart transplant is associated with an increased risk of infec

137 ocyte chimerism in a complex organ such as a transplanted kidney, coupled with the ability to examine

138 escribe 2 cases of renal lymphangiectasia in transplanted kidneys, both from pediatric donors.

139 ed LDKT readiness (47% vs 33%, P = .003) and transplant knowledge (effect size [ES] = 0.41, P < .001)

140 listing while having more social support and transplant knowledge increased the probability of waitli

141 improving readiness to pursue DDKT and LDKT, transplant knowledge, taking 15 small transplant-related

142 Kidney transplant (KT) outcomes for HIV-infected (HIV+) persons

143 mplications (UOC) affect up to 15% of kidney transplants (KTX).

144 , and living-donor and deceased-donor kidney transplants (LDKT/DDKT) March 15-April 30, 2020 to expec

145 In contrast, CD36(High) LSCs were unable to transplant leukemia but were highly proliferative.

146 CA) has been associated with increased heart transplant listings among blacks, who are disproportiona

147 Programs with experience transplanting <23 SLs had a RR of 1.43 (1.21-1.75).

148 ease and poorer outcome as compared to liver transplant (LTx) recipients.

149 In transplant, meaningful international comparisons in orga

150 Transplanted mice were treated with vehicle or di-n-buty

151 ansplant alloantibody production in a murine transplant model.

152 to estimate risk-adjusted predictors of post-transplant mortality.

153 hors provide an overview of the subspecialty transplant nephrology and propose solutions.

154 mouse model, we then tested the capacity of transplanted neural stem cells to restore myelin in the

155 their outgrowths after 2-week cultures were transplanted on the affected eye after pannus resection.

156 ut did not eliminate regional disparities in transplant opportunity without an effect on posttranspla

157 ether donor leukocytes persist within kidney transplants or play any role in rejection is unknown, ho

158 unosuppressants used to prevent rejection of transplanted organs and tissues.

159 s study demonstrates that the routine use of transplant ostomies remains an acceptable practice after

160 enolytics as a potential approach to improve transplant outcomes and availability.

161 s a known risk factor associated with kidney transplant outcomes and is incorporated for determining

162 eeded to draw more definitive conclusions on transplant outcomes and organ utilization.

163 ent travel distance was associated with lung transplant outcomes.

164 obesity was not associated with adverse post-transplant outcomes.

165 e novo DSA formation and potentially improve transplant outcomes.

166 -5.4 bpm vs. 28.5+/-8.9 bpm in those without transplants, p <0.001).

167 (1.35+/-0.19 vs. 1.6+/-0.28 in those without transplants, p=0.003), and a less pronounced hemodynamic

168 (2) vs. 71.4+/-15.9 ml/m(2) in those without transplants, p=0.03), lower MPRI (1.35+/-0.19 vs. 1.6+/-

169 efined iatrogenic and is overall reported in transplanted patient but also, although less frequently,

170 tion, a stratum was created that matched one transplanted patient with all eligible control candidate

171 lating IgG that is currently being tested in transplant patients(8).

172 All waitlisted or previously transplanted patients residing in outbreak areas receive

173 ging on BALB/c nude mice with orthotopically transplanted PC346C tumors.

174 gle-center retrospective cohort of 897 liver transplants performed between June 2009 and September 20

175 ntravenous immunoglobulin depending on their transplant phase and risk profile.

176 Post-transplant positive outcomes are associated with a stead

177 hat included 99 patients with definitive PVN transplanted post January 1, 2009 and followed the origi

178 Patients who had engaged in the kidney transplant process received more intensive patterns of e

179 d provide a more comprehensive assessment of transplant program performance and necessary information

180 Kidney transplant program performance in the United States is c

181 s the experience of the Irish National Liver Transplant Programme with the Mayo Protocol.

182 t electronically to 1643 United States heart transplant providers between June and August 2019.

183 ted time to listing, waitlist mortality, and transplant rate by recurrent falls (>=2 falls) before ev

184 espondents who viewed a note indicating that transplant rate had the largest impact on survival chose

185 on survival chose the hospital with the best transplant rate over the hospital with the best posttran

186 uss key studies in the different solid organ transplants, recent reports of adverse events, and ethic

187 he clinical course and management of a liver transplant recipient on hemodialysis, who presented with

188 e reporting the first case of CG in a kidney transplant recipient with kidney disease of unknown caus

189 -PD-1) for ~9 months to a 57-year-old kidney transplant recipient with metastatic cutaneous squamous

190 ounty-level County Health Ranking data using transplant recipient zip code, and nationwide County Hea

191 es of 7 renal transplant recipients, 1 liver transplant recipient, 1 heart transplant recipient, and

192 ients, 1 liver transplant recipient, 1 heart transplant recipient, and 1 lung transplant recipient.

193 istant Cytomegalovirus retinitis in a kidney transplant recipient.

194 nt, 1 heart transplant recipient, and 1 lung transplant recipient.

195 t recipients from the Scientific Registry of Transplant Recipients (2000-2019).

196 Fifty-five transplant recipients (GNB n = 29; SAB n = 26) and 225 n

197 ctors of obesity among pediatric solid-organ transplant recipients (heart, lung, liver, kidney, multi

198 the MDSC effects on the evolution of kidney transplant recipients (KTRs).

199 ant cause of morbidity and mortality in lung transplant recipients (LTRs).

200 Organ transplant recipients (OTRs) are at increased risk of cu

201 s, we used 2010-2018 Scientific Registry for Transplant Recipients (SRTR) data to identify 92 081 adu

202 cember 2018) comprising 4 transgender kidney transplant recipients and 2 transgender living donors wa

203 Solid organ transplant recipients are at risk for potentially life-t

204 ays during IRI, we treated syngeneic cardiac transplant recipients at 1-hour posttransplant with Anak

205 l and histologic phenotyping from 224 kidney transplant recipients between 2011 and 2017.

206 We applied Scientific Registry of Transplant Recipients data from 2011 to 2016 toward the

207 Using Scientific Registry of Transplant Recipients data, we compared data on observed

208 The Scientific Registry of Transplant Recipients database was reviewed to identify

209 ot be used in high-immunological risk kidney transplant recipients due to a perceived increased risk

210 Two cohorts of kidney transplant recipients enrolled in the Deterioration of K

211 atabase was reviewed to identify adult liver transplant recipients from 2002 through 2016 with MELD s

212 ted 296 807 adult (age > 17) solitary kidney transplant recipients from the Scientific Registry of Tr

213 Elderly organ transplant recipients have remained underrepresented in

214 and recipient CMV-seronegative (D+R-) liver transplant recipients in the current era are incompletel

215 or allo-sensitization in previously tolerant transplant recipients in whom tolerance maintenance is d

216 report four cases of COVID-19 in solid organ transplant recipients including recipients of kidney, li

217 ving this, we studied Scientific Registry of Transplant Recipients kidney offer data for 3642 pediatr

218 DWF and DC-GF in kidney transplant recipients represent differing clinical pheno

219 omes, and chemokine and cytokine response in transplant recipients to immunocompetent, nontransplant

220 9 study in which we randomized stable kidney transplant recipients to Tac withdrawal or maintenance o

221 hput gene expression datasets of solid organ transplant recipients were retrieved from the Gene Expre

222 We included consecutive adult liver transplant recipients who had their surgery between July

223 r retrospective study of stem cell and organ transplant recipients who received letermovir for the tr

224 Among CMV-seronegative liver transplant recipients with seropositive donors, the use

225 reatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipient, 1 h

226 deficits in long-term potentiation (LTP) in transplant recipients, and LTP impairment in TRANSWT mic

227 PA(+/0) mice) and of SR-uPA(+/0) bone marrow transplant recipients, and we used bioinformatic tools t

228 a regarding the risk of cancer recurrence in transplant recipients, the goal of the AST-sponsored con

229 In simultaneous pancreas-kidney (SPK) transplant recipients, the majority of complications des

230 From 1988 consecutive renal transplant recipients, we analyzed 179 patients undergoi

231 Data System, and the Scientific Registry of Transplant Recipients, we compared population-level char

232 Using the Scientific Registry of Transplant Recipients, we studied 110,019 adult deceased

233 bruary 2017 using the Scientific Registry of Transplant Recipients.

234 ading cause of mortality in kidney and liver transplant recipients.

235 tation, rarely occurs in kidney and pancreas transplant recipients.

236 e involved in regulating lung injury in lung transplant recipients.

237 d outcomes of COVID-19 infection among organ transplant recipients.

238 ded: infant ALL, relapsed ALL, and stem cell transplant recipients.

239 y in solid organ and hematopoietic stem cell transplant recipients.

240 new opportunities to improve the outcomes of transplant recipients.

241 s retrospective study included 282 HCC liver transplant recipients.

242 unosuppression in a clinical trial of kidney transplant recipients.

243 as evaluated in 2055 biopsies from 775 renal transplant recipients.

244 r prophylaxis for 100 days in 205 D+R- liver transplant recipients.

245 tment of tacrolimus-induced hyperglycemia in transplant recipients.

246 n uncommon opportunistic infection in kidney transplant recipients.

247 ials of eHealth interventions in solid organ transplant recipients.

248 cted DDD was rare, occurring in 0.18% of all transplant recipients.

249 d organ donors, deceased donor families, and transplant recipients.

250 document contains prognosis, treatment, and transplant recommendations for melanoma and hematologica

251 In this spirit, we discuss an Opt-Out for Transplant Referral Model as a compelling solution to im

252 We examined a national transplant registry for 35 849 T2DM kidney disease patie

253 LDKT, transplant knowledge, taking 15 small transplant-related actions, and pursuing transplant (wai

254 d as the gold standard in the diagnostics of transplant renal artery stenosis (TRAS).

255 s in an alpine plant-pollinator community by transplanting replicated alpine meadow turfs downslope a

256 tified for 10 patients from their first post-transplant RHC, and longitudinal analysis is carried out

257 The liver transplant risk score (LTRS) was developed to stratify 9

258 LD) is reported in the pediatric small bowel transplant (SBTx) population, which may be associated wi

259 ver, immune correlates of EBV DNAemia in the transplant setting are limited.

260 illingness-to-pay threshold to a solid organ transplant setting by coining a new metric: the willingn

261 verage pO2 is important for determining if a transplant site and capsules with certain passive diffus

262 onavirus disease 2019 (COVID-19) solid organ transplant (SOT) patients are limited.

263 responses in HIV-infected adult solid organ transplant (SOT) recipients on antiretroviral therapy.

264 hnologies may offer a solution by addressing transplant-specific barriers: specifically, providing ac

265 ts and providers when vaccines are due using transplant-specific immunization guidelines.

266 unosuppressive medications to maintain their transplant status.

267 keholders such as a transplant hepatologist, transplant surgeon, psychologist and psychiatrist is bec

268 Transplant surgeons are more likely to discard deceased

269 Transplant surgeons can use DonorNet data, including adm

270 d a decrease in total waitlist additions and transplant surgeries.

271 y curative treatment for this condition, but transplant survival in the previously published result w

272 rom the current 36 months to the duration of transplant survival will result in better patient outcom

273 Post-transplant survival with TCS-VAD is superior to ECMO and

274 ntage of combination therapies in prolonging transplant survival.

275 ntified 4 explanted hearts in the context of transplant that received prior SBRT as part of an 11-pat

276 tion (FDA) and the Critical Path Institute's Transplant Therapeutics Consortium convened a public wor

277 The non-transplanted tissues were used for research.

278 immunologists and surgeons exploring immune transplant tolerance owe much to the history of the free

279 cirrhosis, alpha-fetoprotein (AFP) at liver transplant, tumor diameter, tumor pathology, and vascula

280 e priority is to select uninfected donors to transplant uninfected recipients while maintaining safet

281 Uterus transplants (UTxs) have been performed worldwide.

282 ECs that are critical in the pathogenesis of transplant vasculopathy.

283 l options, including vascularized lymph node transplant (VLNT) and lymphovenous bypass (LVB), on pati

284 apid retrieval of up to 94% (+/-3.1%) of the transplant volume 24 h after surgical implantation.

285 Similarly, deceased donor kidney transplant volume dropped from 367 to 202 (-45%), and ot

286 We observed no survival benefit of ECD transplants vs remaining on the waitlist (aHR = 1.05; P

287 all transplant-related actions, and pursuing transplant (waitlisting or LDKT rates) over 8 months.

288 The indication and type of organ transplant were recorded in addition to the amyloidosis

289 Transplanted wild-type cells rescued gonad development b

290 ps, with the exception of high MELD patients transplanted with "high-risk" grafts.

291 ecipients pre-treated with BALB/c MDSCs were transplanted with either donor-type (BALB/c, H2K(d), I-A

292 mouse muscles was not enhanced if they were transplanted with either satellite cells, or myofibres,

293 predict posttransplant survival in patients transplanted with grade-3 acute-on-chronic liver failure

294 Retrospective review for patients transplanted with HCC between April 2008 and June 2017.

295 Consistent with this hypothesis, mice transplanted with T-cells co-expressing NOTCH1 and NRARP

296 1 and NRARP develop leukemia later than mice transplanted with T-NOTCH1 cells.

297 (CI); (3) donor kidneys subjected to kidney transplant without CI (Txp); and (4) donor kidneys subje

298 demonstrated that liver candidates awaiting transplant would benefit from a model employing continuo

299 by coining a new metric: the willingness-to-transplant (WTT) threshold.

300 e compared the effectiveness of Your Path to Transplant (YPT), an individually tailored coaching and